Research programme: diabetic complications therapeutics and diagnostics - Fuso/HuBitAlternative Names: Diabetic complications therapeutics and diagnostics research programme - Fuso/HuBit
Latest Information Update: 16 Jul 2016
At a glance
- Originator Fuso Pharmaceutical Industries; HuBit genomix
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Diabetic complications
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic-complications in Japan
- 15 Feb 2005 Preclinical trials in Diabetic complications in Japan (unspecified route)